Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Keyphrases

• Type 2 Diabetes Mellitus (T2DM) 100%
• Dose Adjustment 100%
• Flexible Dose 100%
• Sitagliptin 100%
• Oral Semaglutide 100%
• Estimand 58%
• Hemoglobin A1c (HbA1c) 41%
• Treatment Policy 33%
• Adverse Events 16%
• Receptor Agonist 16%
• Once-daily 16%
• Glucose-lowering Drugs 16%
• A1 Receptor 16%
• Glucagon-like 16%
• Tolerability 16%
• One Dose 16%
• Treatment Difference 16%
• Rescue Medication 16%
• Nausea 8%
• South Korea 8%
• Odds Ratio 8%
• Oral Formulation 8%
• Safety Profile 8%
• Weight Loss 8%
• Type 2 Diabetic Patients 8%
• Clinical Practice 8%
• Daily Dose 8%
• Response System 8%
• Glycemic Control 8%
• Type 2 Diabetes Prevention 8%
• EudraCT 8%
• Efficacy Endpoint 8%
• Clinical Database 8%
• Interactive Web Response 8%
• Baseline HbA1c 8%
• Treatment Use 8%
• Treatment Discontinuation 8%
• Open-label Extension 8%
• Patient-assessed 8%
• Loss of Control 8%
• Treatment Personalization 8%
• Novo Nordisk 8%

Medicine and Dentistry

• Maturity Onset Diabetes of the Young 100%
• Sitagliptin 100%
• Semaglutide 100%
• Hemoglobin A1c 50%
• Drug Therapy 25%
• Adverse Event 16%
• Glucagon-Like Peptide-1 Agonist 16%
• Clinical Trial 8%
• Patient with Type 2 Diabetes 8%
• Nausea 8%
• Glycemic Control 8%
• Individualization 8%
• Odds Ratio 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Sitagliptin 100%
• Semaglutide 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Hemoglobin A1c 50%
• Adverse Event 16%
• Tolerability 16%
• Glucagon Like Peptide 1 Receptor Agonist 16%
• Nausea 8%
• Clinical Trial 8%